Navigation Links
U.S. Supreme Court Rules Generic Drug Makers Can’t Be Sued for Design Defects Under State Law, Rottenstein Law Group LLP Reports
Date:6/24/2013

(PRWEB) June 24, 2013

On June 24 the U.S. Supreme Court ruled 5-4 that makers of generic drugs can’t be held liable under state laws for the design defects of the drugs they manufacture. The Rottenstein Law Group LLP, which represents clients in drug injury lawsuits, is disappointed with the ruling, but emphasizes that this ruling does not affect those who believe they were injured by their brand-name drugs.

In its ruling in Mutual Pharmaceutical Co., Inc. v Bartlett,* the Court said that federal law and regulations preempt the state-law design-defect claim of victim Karen Bartlett, who alleged that she developed disfigurements related to toxic epidermal necrolysis (TEN) after taking sulindac, the generic form of the drug Clinoril she was prescribed in 2004. Sulindac manufacturer Mutual, as with other generic drug makers, is required by law to make generic drugs the same as their brand-name counterparts and to maintain the same warning labels. In this instance, Mutual did not include a warning about TEN on the sulindac label because the original drug’s label did not have the warning. It was not until 2005 that the U.S. Food and Drug Administration recommended changing all labeling for sulindac-type drugs to reflect the TEN risk.

“This is certainly not the ruling we would have hoped for,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “But anyone who believes he or she has been harmed by a medication should speak to a lawyer to determine whether there is a viable claim to be made.”

Bartlett had originally sued Mutual in New Hampshire state court, but Mutual removed the case to federal court, according to the ruling. The federal jury awarded Bartlett $21 million, which was affirmed in the appeals court. The Supreme Court was the next court to consider the case.

The Rottenstein Law Group LLP’s Dangerous Drugs page provides more information on drug side effects, news and lawsuits.

*http://www.supremecourt.gov/opinions/12pdf/12-142_8njq.pdf

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at injurylawyernewswire.com. Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/generic-drugs-lawsuits/supreme-court-ruling/prweb10864294.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. America Awaits Supreme Courts Ruling on Health Care Reform
2. Supreme Court Surprises in Citizens United Montana Case, Delays Order
3. Supreme Court Backs Much of Controversial Health Reform Law
4. Coral Calcium Company Announces New Offer Amidst Supreme Court Healthcare Decisions
5. Supreme Court Ruling Sets Stage for Full Rollout of Health-Care Reform Law
6. Cell Phone Radiation Lawsuit Update: ICEMS Position Paper Supports Italian Supreme Court Ruling on Cell Phones and Brain Tumors, Bernstein Liebhard LLP Reports
7. Human Gene Patent Case Goes to Supreme Court
8. U.S. Supreme Court Rejects Challenge to New Cigarette Labeling
9. New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury
10. Mirena IUD Lawsuit Update: Supreme Court of New Jersey Centralizes Litigation; Parker Waichman LLP Underscores the Advantages of this Decision
11. U.S. Supreme Court Invalidates Patents on Breast and Ovarian Cancer Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
Breaking Medicine Technology: